TREK1 channel activation as a new analgesic strategy devoid of opioid adverse effects

ARRIVE 2.0 and the British Journal of Pharmacology: Updated guidance for 2020

(2020) Elliott Lilley et al.   BRITISH JOURNAL OF PHARMACOLOGY

The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research

(2020) Nathalie Percie du Sert et al.   PLOS BIOLOGY

A pharmacological master key mechanism that unlocks the selectivity filter gate in K+ channels

(2019) Marcus Schewe et al.   SCIENCE

Molecular determinants of chemical modulation of two‐pore domain potassium channels

(2019) Daniel Șterbuleac   Chemical Biology & Drug Design

A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists

(2019) Kendall L. Mores et al.   Frontiers in Pharmacology

Pranlukast is a novel small molecule activator of the two-pore domain potassium channel TREK2

(2019) Paul D. Wright et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Ion channels

(2019) Stephen P H Alexander et al.   BRITISH JOURNAL OF PHARMACOLOGY

Experimental design and analysis and their reporting II: updated and simplified guidance for authors and peer reviewers

(2018) Michael J Curtis et al.   BRITISH JOURNAL OF PHARMACOLOGY

Role of mGlu7 receptor in morphine rewarding effects is uncovered by a novel orthosteric agonist

(2018) Zuzana Hajasova et al.   NEUROPHARMACOLOGY

Protein and Chemical Determinants of BL-1249 Action and Selectivity for K2P Channels

(2018) Lianne Pope et al.   ACS Chemical Neuroscience

Targeting the TREK-1 potassium channel via riluzole to eliminate the neuropathic and depressive-like effects of oxaliplatin

(2018) Laura Poupon et al.   NEUROPHARMACOLOGY

A bifunctional nociceptin and mu opioid receptor agonist is analgesic without opioid side effects in nonhuman primates

(2018) Huiping Ding et al.   Science Translational Medicine

Abuse Potential of Biased Mu Opioid Receptor Agonists

(2018) S. Stevens Negus et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Effects of S 38093, an antagonist/inverse agonist of histamine H3 receptors, in models of neuropathic pain in rats

(2017) T. Chaumette et al.   EUROPEAN JOURNAL OF PAIN

Development of the First Two-Pore Domain Potassium Channel TWIK-Related K+ Channel 1-Selective Agonist Possessing in Vivo Antinociceptive Activity

(2017) Delphine Vivier et al.   JOURNAL OF MEDICINAL CHEMISTRY

K2P2.1 (TREK-1)–activator complexes reveal a cryptic selectivity filter binding site

(2017) Marco Lolicato et al.   NATURE

The Role of Science in Addressing the Opioid Crisis

(2017) Nora D. Volkow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genetic dissociation of morphine analgesia from hyperalgesia in mice

(2017) Gina F. Marrone et al.   PSYCHOPHARMACOLOGY

A nontoxic pain killer designed by modeling of pathological receptor conformations

(2017) V. Spahn et al.   SCIENCE

Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity

(2017) Alaeddine Djillani et al.   Frontiers in Pharmacology

Structure-based discovery of opioid analgesics with reduced side effects

(2016) Aashish Manglik et al.   NATURE

Synthesis and structure–activity relationship study of substituted caffeate esters as antinociceptive agents modulating the TREK-1 channel

(2014) Nuno Rodrigues et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

A High-Throughput Functional Screen Identifies Small Molecule Regulators of Temperature- and Mechano-Sensitive K2P Channels

(2013) Sviatoslav N. Bagriantsev et al.   ACS Chemical Biology

Activation of TREK-1 by morphine results in analgesia without adverse side effects

(2013) Maïly Devilliers et al.   Nature Communications

Variants of Stretch-Activated Two-Pore Potassium Channel TREK-1 Associated with Preterm Labor in Humans1

(2012) Yi-Ying Wu et al.   BIOLOGY OF REPRODUCTION

The role of the NMDA receptors and l-arginine–nitric oxide–cyclic guanosine monophosphate pathway in the antidepressant-like effect of duloxetine in the forced swimming test

(2012) Andréa D.E. Zomkowski et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Spadin as a new antidepressant: Absence of TREK-1-related side effects

(2011) H. Moha ou Maati et al.   NEUROPHARMACOLOGY

Anabolic–androgenic steroid effects on nociception and morphine antinociception in male rats

(2011) K.T. Tsutsui et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Nav1.9 Channel Contributes to Mechanical and Heat Pain Hypersensitivity Induced by Subacute and Chronic Inflammation

(2011) Stéphane Lolignier et al.   PLoS One

A Human TREK-1/HEK Cell Line: A Highly Efficient Screening Tool for Drug Development in Neurological Diseases

(2011) Hamid Moha ou Maati et al.   PLoS One

Truncated G protein-coupled mu opioid receptor MOR-1 splice variants are targets for highly potent opioid analgesics lacking side effects

(2011) S. Majumdar et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Spadin, a Sortilin-Derived Peptide, Targeting Rodent TREK-1 Channels: A New Concept in the Antidepressant Drug Design

(2010) Jean Mazella et al.   PLOS BIOLOGY

Animal models and the prediction of efficacy in clinical trials of analgesic drugs: A critical appraisal and call for uniform reporting standards

(2008) Andrew S.C. Rice et al.   PAIN